ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $1,253,000 | -2.7% | 10,674 | +11.5% | 0.02% | -4.3% |
Q4 2021 | $1,288,000 | -14.8% | 9,576 | +0.9% | 0.02% | -14.8% |
Q3 2021 | $1,512,000 | +13.2% | 9,488 | -6.6% | 0.03% | +3.8% |
Q2 2021 | $1,336,000 | +12.6% | 10,159 | +10.3% | 0.03% | 0.0% |
Q1 2021 | $1,187,000 | +4.0% | 9,212 | +34.7% | 0.03% | -7.1% |
Q4 2020 | $1,141,000 | +189.6% | 6,841 | +95.6% | 0.03% | -6.7% |
Q1 2020 | $394,000 | -46.7% | 3,497 | -34.1% | 0.03% | +50.0% |
Q4 2019 | $739,000 | +45.2% | 5,309 | +18.9% | 0.02% | +5.3% |
Q2 2019 | $509,000 | +6.7% | 4,466 | +10.3% | 0.02% | -5.0% |
Q1 2019 | $477,000 | +61.1% | 4,049 | -14.3% | 0.02% | +53.8% |
Q4 2018 | $296,000 | -13.7% | 4,722 | -2.4% | 0.01% | -7.1% |
Q3 2018 | $343,000 | +3.9% | 4,839 | -2.6% | 0.01% | -6.7% |
Q2 2018 | $330,000 | +55.7% | 4,967 | +53.5% | 0.02% | +50.0% |
Q1 2018 | $212,000 | – | 3,236 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |